Background: Histopathological alterations and a reduced number of capillaries have been observed in the palate muscles of snorers with obstructive sleep apnea syndrome (OSAS). These changes may create a substrate for decreased microcirculation, impaired aerobic metabolism and muscle dysfunction and contribute to upper airway obstruction during sleep. Objectives: The aim was to analyze mitochondria distribution and oxidative enzyme activity in relation to capillary supply in the palate muscles of patients with a history of long-term snoring and OSAS. Methods: Palatopharyngeus (PP) and uvula (UV) muscle samples were obtained from 8 patients undergoing uvulopalatopharyngoplasty due to habitual snoring and OSAS. The muscles were analyzed with enzyme- and immunohistochemistry and morphometry. Results: Abnormalities in the internal organization of mitochondria and oxidative activity were observed in 39 ± 15% of the fibers in the PP and 4 ± 3% in the UV, but not in control samples. The majority of these fibers had a lobulated contour and trabecular internal organization of mitochondria. The number of capillaries around abnormal fibers (PP 0.9 ± 0.3, UV 0.4 ± 0.1) was lower than in fibers of a normal appearance in both patients (PP 1.4 ± 0.6, UV 1.2 ± 0.3) and references (PP 2.7 ± 0.7, UV 1.9 ± 0.9) (p < 0.05). Conclusions: Abnormal mitochondrial distribution, a low capillary supply and signs of impaired oxidative activity suggest that muscle dysfunction of the palate muscles in long-term snorers may contribute to the upper airway obstruction during sleep. The cause of these abnormalities remains unclear, but local muscle and nerve trauma due to vibration and stretch is a possible etiology.

1.
Young T, Palta M, Dempsey J, Skatrud J, Weber S, Badr S: The occurrence of sleep-disordered breathing among middle-aged adults. N Engl J Med 1993;328:1230–1235.
2.
Dempsey JA, Veasey SC, Morgan BJ, O’Donnell CP: Pathophysiology of sleep apnea. Physiol Rev 2010;90:47–112.
3.
Hudgel DW: Mechanisms of obstructive sleep apnea. Chest 1992;101:541–549.
4.
Shepard JW Jr, Thawley SE: Localization of upper airway collapse during sleep in patients with obstructive sleep apnea. Am Rev Respir Dis 1990;141:1350–1355.
5.
Morrison DL, Launois SH, Isono S, Feroah TR, Whitelaw WA, Remmers JE: Pharyngeal narrowing and closing pressures in patients with obstructive sleep apnea. Am Rev Respir Dis 1993;148:606–611.
6.
Edström L, Larsson H, Larsson L: Neurogenic effects on the palatopharyngeal muscle in patients with obstructive sleep apnoea: a muscle biopsy study. J Neurol Neurosurg Psychiatry 1992;55:916–920.
7.
Friberg D, Ansved T, Borg K, Carlsson- Nordlander B, Larsson H, Svanborg E: Histological indications of progressive snorer’s disease in an upper airway muscle. Am J Respir Crit Care Med 1998;157:586–593.
8.
Friberg D: Heavy snorer’s disease: a progressive local neuropathy. Acta Otolaryngol 1999;119:925–933.
9.
Lindman R, Stål PS: Abnormal palatopharyngeal muscle morphology in sleep-disordered breathing. J Neurol Sci 2002;195:11–23.
10.
Woodson BT, Garancis JC, Toohill RJ: Histopathologic changes in snoring and obstructive sleep apnea syndrome. Laryngoscope 1991;101:1318–1322.
11.
Boyd JH, Petrof BJ, Hamid Q, Fraser R, Kimoff RJ: Upper airway muscle inflammation and denervation changes in obstructive sleep apnea. Am J Respir Crit Care Med 2004;170:541–546.
12.
Stål PS, Lindman R, Johansson B: Capillary supply of the soft palate muscles is reduced in long-term habitual snorers. Respiration 2009;77:303–310.
13.
Eriksson PO, Eriksson A, Ringqvist M, Thornell LE: The reliability of histochemical fibre typing of human necropsy muscles. Histochemistry 1980;65:193–205.
14.
Dubowitz V, Sewry A: Muscle Biology. A Practical Approach, ed 3. London, Saunders Elsevier, 2007.
15.
Stål PS, Lindman R: Characterisation of human soft palate muscles with respect to fibre types, myosins and capillary supply. J Anat 2000;197:275–290.
16.
Pontén EM, Stål PS: Decreased capillarization and a shift to fast myosin heavy chain IIx in the biceps brachii muscle from young adults with spastic paresis. J Neurol Sci 2007;253:25–33.
17.
Hughes SM, Cho M, Karsch-Mizrachi I, Travis M, Silberstein L, Leinwand LA, Blau HM: Three slow myosin heavy chains sequentially expressed in developing mammalian skeletal muscle. Dev Biol 1993;158:183–199.
18.
Cho M, Webster SG, Blau HM: Evidence for myoblast-extrinsic regulation of slow myosin heavy chain expression during muscle fiber formation in embryonic development. J Cell Biol 1993;121:795–810.
19.
Liu JX, Eriksson PO, Thornell LE, Pedrosa-Domellof F: Myosin heavy chain composition of muscle spindles in human biceps brachii. J Histochem Cytochem 2002;50:171–183.
20.
Silberstein L, Webster SG, Travis M, Blau HM: Developmental progression of myosin gene expression in cultured muscle cells. Cell 1986;46:1075–1081.
21.
Weiss A, Schiaffino S, Leinwand LA: Comparative sequence analysis of the complete human sarcomeric myosin heavy chain family: implications for functional diversity. J Mol Biol 1999;290:61–75.
22.
Ecob-Prince M, Hill M, Brown W: Immunocytochemical demonstration of myosin heavy chain expression in human muscle. J Neurol Sci 1989;91:71–78.
23.
Tiger CF, Champliaud MF, Pedrosa-Domellöf F, Thornell LE, Ekblom P, Gullberg D: Presence of laminin alpha5 chain and lack of laminin alpha1 chain during human muscle development and in muscular dystrophies. J Biol Chem 1997;272:28590–28595.
24.
Sewry CA, Philpot J, Mahony D, Wilson LA, Muntoni F, Dubowitz V: Expression of laminin subunits in congenital muscular dystrophy. Neuromuscul Disord 1995;5:307–316.
25.
Bethlem J, van Wijngaarden GK, de Jong J: The incidence of lobulated fibres in the facioscapulo-humeral type of muscular dystrophy and the limb-girdle syndrome. J Neurol Sci 1973;18:351–358.
26.
Weller B, Carpenter S, Lochmuller H, Karpati G: Myopathy with trabecular muscle fibers. Neuromuscul Disord 1999;9:208–214.
27.
Figarella-Branger D, El-Dassouki M, Saenz A, Cobo AM, Malzac P, Tong S, Cassotte E, Azulay JP, Pouget J, Pellissier JF: Myopathy with lobulated muscle fibers: evidence for heterogeneous etiology and clinical presentation. Neuromuscul Disord 2002;12:4–12.
28.
Guerard MJ, Sewry CA, Dubowitz V: Lobulated fibers in neuromuscular diseases. J Neurol Sci 1985;69:345–356.
29.
Butler-Browne GS, Whalen RG: Myosin isozyme transitions occurring during the postnatal development of the rat soleus muscle. Dev Biol 1984;102:324–334.
30.
Banker BQ, Engel AG: Myology, ed 2. New York, Mc Graw-Hill, 1994.
31.
Borisov AB, Huang SK, Carlson BM: Remodeling of the vascular bed and progressive loss of capillaries in denervated skeletal muscle. Anat Rec 2000;258:292–304.
32.
Taylor RW, Schaefer AM, Barron MJ, McFarland R, Turnbull DM: The diagnosis of mitochondrial muscle disease. Neuromuscul Disord 2004;14:237–245.
33.
Johannsen DL, Ravussin E: The role of mitochondria in health and disease. Curr Opin Pharmacol 2009;9:780–786.
34.
Lavie L: Obstructive sleep apnoea syndrome – an oxidative stress disorder. Sleep Med Rev 2003;7:35–51.
35.
Chariot P, Ruet E, Authier FJ, Labes D, Poron F, Gherardi R: Cytochrome c oxidase deficiencies in the muscle of patients with inflammatory myopathies. Acta Neuropathol 1996;91:530–536.
36.
Nardin RA, Johns DR: Mitochondrial dysfunction and neuromuscular disease. Muscle Nerve 2001;24:170–191.
37.
Rifai Z, Welle S, Kamp C, Thornton CA: Ragged red fibers in normal aging and inflammatory myopathy. Ann Neurol 1995;37:24–29.
38.
Takeuchi T, Futasuka M, Imanishi H, Yamada S: Pathological changes observed in the finger biopsy of patients with vibration-induced white finger. Scand J Work Environ Health 1986;12:280–283.
39.
Koskimies K, Farkkila M, Pyykko I, Jantti V, Aatola S, Starck J, Inaba R: Carpal tunnel syndrome in vibration disease. Br J Ind Med 1990;47:411–416.
40.
Virokannas H: Vibration perception thresholds in workers exposed to vibration. Int Arch Occup Environ Health 1992;64:377–382.
41.
Murfee WL, Hammett LA, Evans C, Xie L, Squire M, Rubin C, Judex S, Skalak C: High-frequency, low-magnitude vibrations suppress the number of blood vessels per muscle fiber in mouse soleus muscle. J Appl Physiol 2005;98:2376–2380.
42.
Stoyneva Z, Lyapina M, Tzvetkov D, Vodenicharov E: Current pathophysiological views on vibration-induced Raynaud’s phenomenon. Cardiovasc Res 2003;57:615–624.
43.
Fukagawa Y, Otsu M, Nakano M, Maki T: Analysis of capillary fluid flow rate by vibration on a small vessel model. J UOEH 1986;8:159–168.
44.
Curry BD, Bain JL, Yan JG, Zhang LL, Yamaguchi M, Matloub HS, Riley DA: Vibration injury damages arterial endothelial cells. Muscle Nerve 2002;25:527–534.
45.
Farkkila M: Grip force in vibration disease. Scand J Work Environ Health 1978;4:159–166.
46.
Heffner RR BS: The early effects of ischemia upon skeletal muscle mitochondria. J Neurol Sci 1978;38:295–315.
47.
Carpenter S KG: Pathologhy of skeletal muscle. New York, Churchill Livingstone, 1984.
48.
Clarkson PM, Hubal MJ: Exercise-induced muscle damage in humans. Am J Phys Med Rehabil 2002;81:S52–S69.
49.
Fridén J, Sjöström M, Ekblom B: Myofibrillar damage following intense eccentric exercise in man. Int J Sports Med 1983;4:170–176.
50.
Horner RL: Pathophysiology of obstructive sleep apnea. J Cardiopulm Rehabil Prev 2008;28:289–298.
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.